Literature DB >> 17160144

The promise of canonical Wnt signaling modulators in enhancing bone repair.

Carl A Gregory1, Angela Green, Narae Lee, Ashwin Rao, William Gunn.   

Abstract

The skeleton is vitally important for support, mechanical function and protection of internal organs. Over the last few decades, the molecular mechanisms by which bones develop and repair themselves have been the subject of intense research throughout the world. Particular attention has been paid to mesenchymal progenitors and the regulation of their differentiation to osteoblasts, the cells that build and repair bone. One of the major findings of these studies is that positive signaling by the canonical wingless (Wnt) pathway in mesenchymal progenitor cells is critical for the differentiation of the progenitors into osteoblasts. The subject of this review focuses on how perturbations of the Wnt pathway can adversely affect osteogenesis in disease and also, how pharmaceutical modulators of the Wnt pathway may be employed in the future to inhibit degenerative diseases of the bone and enhance repair. (c) 2006 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160144     DOI: 10.1358/dnp.19.8.1043960

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  9 in total

1.  Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model.

Authors:  W Grady Gunn; Ulf Krause; Narae Lee; Carl A Gregory
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

2.  Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy.

Authors:  Ulf Krause; Sean Harris; Angela Green; Joni Ylostalo; Suzanne Zeitouni; Narae Lee; Carl A Gregory
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-11       Impact factor: 11.205

3.  Secreted frizzled related protein 1 is a target to improve fracture healing.

Authors:  Tripti Gaur; John J Wixted; Sadiq Hussain; Shannon L O'Connell; Elise F Morgan; David C Ayers; Barry S Komm; Peter V Bodine; Gary S Stein; Jane B Lian
Journal:  J Cell Physiol       Date:  2009-07       Impact factor: 6.384

Review 4.  The Effect of Space Travel on Bone Metabolism: Considerations on Today's Major Challenges and Advances in Pharmacology.

Authors:  Shirley Genah; Monica Monici; Lucia Morbidelli
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

5.  Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death.

Authors:  Francesco Piazza; Sabrina Manni; Laura Quotti Tubi; Barbara Montini; Laura Pavan; Anna Colpo; Marianna Gnoato; Anna Cabrelle; Fausto Adami; Renato Zambello; Livio Trentin; Carmela Gurrieri; Gianpietro Semenzato
Journal:  BMC Cancer       Date:  2010-10-04       Impact factor: 4.430

6.  Rapid Osteogenic Enhancement of Stem Cells in Human Bone Marrow Using a Glycogen-Synthease-Kinase-3-Beta Inhibitor Improves Osteogenic Efficacy In Vitro and In Vivo.

Authors:  Bret H Clough; Suzanne Zeitouni; Ulf Krause; Christopher D Chaput; Lauren M Cross; Akhilesh K Gaharwar; Carl A Gregory
Journal:  Stem Cells Transl Med       Date:  2018-02-05       Impact factor: 6.940

7.  Glycogen synthase kinase 3β promotes osteogenic differentiation of murine adipose-derived stromal cells.

Authors:  Jeong-Eun Huh; Ryeojin Ko; Hyun Ju Jung; Soo Young Lee
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

8.  A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies.

Authors:  N Lee; A J Smolarz; S Olson; O David; J Reiser; R Kutner; N C Daw; D J Prockop; E M Horwitz; C A Gregory
Journal:  Br J Cancer       Date:  2007-11-06       Impact factor: 7.640

9.  Spinal cord injury causes bone loss through peroxisome proliferator-activated receptor-γ and Wnt signalling.

Authors:  Jun Yan; Bo Li; Jiang-Wei Chen; Sheng-Dan Jiang; Lei-Sheng Jiang
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.